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Structure-Guided Design Affirms Inhibitors of Hepatitis
C Virus p7 as a Viable Class of Antivirals Targeting
Virion Release
Toshana L. Foster,1,2 Gary S. Thompson,2 Arnout P. Kalverda,2 Jayakanth Kankanala,3
Matthew Bentham,1 Laura F. Wetherill,1 Joseph Thompson,3 Amy M. Barker,2 Dean Clarke,2
Marko Noerenberg,2 Arwen R. Pearson,2 David J. Rowlands,2 Steven W. Homans,2 Mark Harris,2*
Richard Foster,3* and Stephen Griffin1,2
Current interferon-based therapy for hepatitis C virus (HCV) infection is inadequate,
prompting a shift toward combinations of direct-acting antivirals (DAA) with the first
protease-targeted drugs licensed in 2012. Many compounds are in the pipeline yet pri-
marily target only three viral proteins, namely, NS3/4A protease, NS5B polymerase, and
NS5A. With concerns growing over resistance, broadening the repertoire for DAA tar-
gets is a major priority. Here we describe the complete structure of the HCV p7 protein
as a monomeric hairpin, solved using a novel combination of chemical shift and nuclear
Overhauser effect (NOE)-based methods. This represents atomic resolution information
for a full-length virus-coded ion channel, or “viroporin,” whose essential functions rep-
resent a clinically proven class of antiviral target exploited previously for influenza A
virus therapy. Specific drug-protein interactions validate an allosteric site on the channel
periphery and its relevance is demonstrated by the selection of novel, structurally diverse
inhibitory small molecules with nanomolar potency in culture. Hit compounds repre-
sent a 10,000-fold improvement over prototypes, suppress rimantadine resistance poly-
morphisms at submicromolar concentrations, and show activity against other HCV
genotypes. Conclusion: This proof-of-principle that structure-guided design can lead to
drug-like molecules affirms p7 as a much-needed new target in the burgeoning era of
HCV DAA. (HEPATOLOGY 2014;59:408-422)
M
any global viral pathogens encode essential
ion channel proteins, so-called “viroporins,”
representing an important opportunity for
antiviral development. Clinical precedent was set by
adamantane inhibitors of influenza A virus (IAV) M2
in the 1960s, yet widespread resistance limits their cur-
rent use. However, viroporins retain potential as antivi-
ral targets amenable to modern-day drug development.
Hepatitis C virus (HCV) infects 170 million indi-
viduals, causing severe liver disease and hepatocellular
carcinoma (HCC). HCV encodes a cation-selective
viroporin, p7,1-3 which is essential in vivo4 and
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required for efficient secretion of virions.5,6 p7 has
been described to perform at least two distinct func-
tions in culture: an early role interacting with NS2,7-11
as well as a late-acting function as an oligomeric pro-
ton channel that dissipates pH gradients in secretory
vesicles, potentially protecting acid-labile intracellular
virions during egress.12 Several prototype p7 inhibitors
block channel activity and release of infectivity in a
strain-dependent fashion.13-16 However, prototype
potency is low and clinical trial data have been uncon-
vincing.17,18 Recently, we identified specific resistance
polymorphisms that indicated the likely modes of
action for two p7 inhibitor prototypes: adamantanes
targeted a membrane-exposed allosteric site on the
channel periphery to stabilize closed channel com-
plexes, whereas nonylated imino-sugars prevented
channel oligomerization.15
A lack of atomic structural information has hindered
the development of bespoke p7 inhibitors. p7 comprises
two trans-membrane (TM) helices and forms hexameric
and/or heptameric channel complexes,1,19,20 with activ-
ity influenced by membrane composition.21 Elegant
electron microscopy reconstructions (16 A˚ resolution)
revealed flower-like hexameric complexes formed by
genotype 2a p7 in detergent micelles,20 although short
detergent chain length may broaden this structure.22 A
conserved His17 (primarily genotypes 1, 3, and 4) has
been shown biochemically to line the channel lumen,23
comprising the N-terminal TM region. p7 structural
investigations have been undertaken using both
solution-nuclear magnetic resonance (sNMR) and solid-
state NMR (ssNMR). sNMR in 50% tri-fluoro-ethanol
(TFE) yielded secondary structure elements, but no
information on 3D fold or long-range interactions, limit-
ing outputs to a molecular dynamics (MD) model.24
ssNMR studies support models where p7 TM domains
split into four separate helical regions, tilted relative to the
membrane normal,25,26 yet a full structure remains elusive.
Here we describe the complete sNMR structure of
monomeric FLAG-tagged p7 (FLAG-p7) in a structurally
relevant hairpin conformation. Supported by specific
protein-drug interactions, this structure serves as an accurate
template for the selection of novel, highly potent virion
release inhibitors. Modified derivatives based on initial hits
suggest that subsequently derived lead molecules could lead
to an HCV-targeted drug, creating a valuable addition to
future drug combinations necessary to combat the emer-
gence of resistant HCV.
Materials and Methods
Isotopically Labeled FLAG-p7. Expression and
purification (reverse-phase high-performance liquid chro-
matography [rp-HPLC]) of FLAG-p7 has been
described.13,15,19,27,28 Escherichia coli BL21(DE3) trans-
formed with pGEX-FLAG-p7 (genotype (GT)1b J4 iso-
late wild-type, L20F) were grown at 30C until an OD600
of 0.8 in M9 minimal media, with 15N ammonium chlo-
ride (1 g/L), 13C glucose (2 g/L), 0.04% FeCl(III), and
BME vitamins (Sigma-Aldrich). Expression was induced
overnight with shaking at 30C using 1 mM IPTG.
NMR Spectroscopy and Structure Calculation. A
detailed description of NMR experiments and struc-
ture calculation protocols is provided in the Sup-
porting Experimental Procedures section. NMR
analysis of [13C, 15N]-FLAG-p7 (0.3-0.6 mM) in
100% MeOH was conducted using Varian Inova
500, 600, or 750 (cold-probe) MHz spectrometers
at 25C. Structure calculation employed a novel pro-
tocol where a chemical shift derived structure was first
calculated using cs-memrosetta,29 providing secondary
structure characteristics. Semirigidified secondary struc-
tural elements were then refined against observed
nuclear Overhauser effects (NOEs) using Aria 2.3.30
Table 1 shows NMR and refinement statistics.
Structure-Guided p7 Channel Models. Models
were generated manually within Maestro (Schro-
dinger). Seven monomers were colocated around a
centroid based on a requirement for common distance
and angle between common atoms on individual
monomers. The monomer stack was then tilted to
allow for pore constriction at the loop region, and tilt
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towards adjacent monomers required for packing. The
model was then symmetrized using the measuring tool
and the angle-adjust options with respect to the cent-
roid. Models were energy minimized using the MMFF
tool in Macromodel in an octanol environment. Itera-
tive refinement generated a model with the lowest
global energy. Models for other genotypes were derived
from the J4 model with subsequent energy minimiza-
tion. Lumenal diameters were calculated using the
“Hollow”31 and Pymol (DeLano Scientific).
In Silico Compound Selection. A commercially
available compound library (250K1 compounds) was
screened against one of the seven allosteric binding
sites present on the structure-guided channel model,
defined by Leu20, using eHiTS (SymBioSys). The
highest-ranking 2,000 were then redocked using
eHiTS (high accuracy). Compounds were selected by
raw eHiTS scores, requirement for drug-likeness, and
lack of reactive functionality. The top 30 compounds
were redocked in Glide (Schrodinger) and these coor-
dinates used for the modeling studies described herein.
In Vitro Assays for p7 Channel Activity. Lipo-
some carboxyfluorescein release assays were conducted
as described previously.13,15,28
HCV Culture. Huh7 cells were maintained, trans-
fected, and treated with inhibitors for 72 hours as
described.13,15 Experiments employed JFH-1 (genotype
2a) subgenomic firefly luciferase replicon, full-length
JFH-1, or chimeras encoding C-E1-E2-p7-NS2 pro-
teins from other genotypes: 1b (J4), H77 (1a) J6 (2a),
S52 (3a), and ED43 (4a). J4/JFH-1 Leu20Phe was
generated by polymerase chain reaction (PCR) muta-
genesis (details available upon request). Commercially
available MTT (3-(4,5-dimethylthiazol-2-yl)22,5-
diphenyltetrazolium bromide) toxicity assays were car-
ried out according to the manufacturer’s instructions
(Roche).
Protein Analysis. Western blots of Huh7 lysates
and immunofluorescence analysis at 72 hours post-
transfection used rabbit anti-core (308), mouse anti-E2
(AP33), rabbit anti-NS2, sheep anti-NS5A, and mouse
anti-glyceraldehyde 3-phosphate dehydrogenase (6CS,
Invitrogen), with appropriate horseradish peroxidase-
conjugated (Sigma) or Alexa-Fluor conjugated (Invitro-
gen) secondary antibodies. Protocols as described.13,32
Results
Solution Structure of Monomeric FLAG-
p7. sNMR was conducted in methanol (MeOH),
reconstitution in which preserves FLAG-p7 in a func-
tional, drug-sensitive state upon introduction to mem-
branes (Supporting Fig. S1a).13,28 Importantly,
biochemical and biophysical analysis confirmed FLAG-
p7 to be both monomeric and in a helical fold when
reconstituted in MeOH (intrinsic tryptophan fluores-
cence quenching, sedimentation velocity analytical
ultracentrifugation, Fig. S1b-d). MeOH was preferable
to 50% TFE, reconstitution in which reduced both p7
functionality and compound sensitivity in subsequent
dye release assays (data not shown), as well as to 1,2-
diheptanoyl-sn-glycero-3-phosphocholine (DHPC)
which induced FLAG-p7 oligomerization in our hands
(Fig. S1b,d). Critically, labeled FLAG-p7 was shown
to form a hairpin by paramagnetic relaxation enhance-
ment (PRE) (Fig. S1e). However, data were excluded
from structure calculations due to chemical shift
changes induced by both mutagenesis (Cys0 added at
p7 amino-terminus, with C27S) and labeling (MTSL
reagent added to either Cys0/27) (data not shown).
FLAG-p7 yielded well-resolved, fully assignable, dis-
persed 1H-15N correlation spectra consistent with a
predominant helical fold (Fig. S2d,e). While de novo
structure calculations yielded hairpin structures, orien-
tation of the C-terminus relative to the N-terminal
helix could not be unambiguously defined (Fig. S2a).
Table 1. NMR and Refinement Statistics for Protein
Structures
Protein
NMR distance and dihedral constraints
Distance constraints
Total NOE 512 restraints from 304 peaks
Intra-residue 214
Inter-residue 298
Sequential (|i – j|5 1) 106
Medium-range (|i – j| 4) 161
Long-range (|i – j|> 4) 61
Total dihedral angle restraints 104
/ 52
w 52
Structure statistics
Violations (mean and s.d.)
Distance constraints (A˚) 0.0078 60.0003
Dihedral angle constraints () 1.36 0.7
Max. dihedral angle violation () 2.26 0.6
Max. distance constraint violation (A˚) 0.0 0.0
Deviations from idealized geometry
Bond lengths (A˚) 0.003236 0.00009
Bond angles () 0.5606 0.006
Impropers () 0.4626 0.016
Average pairwise r.m.s. deviation** (A˚)
Heavy 0.876
Backbone 0.306
**Pairwise r.m.s. deviations were calculated over residues 216 to 57 from
the best 20 refined structures sorted by energy.
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Therefore, a chemical shift-based model of FLAG-p7
secondary structure elements was retained as semirigid
helical domains refined against the 512 observed NOE
constraints during the Aria structure calculation proto-
col, allowing all other degrees of freedom to evolve.
The final series of 20 calculated structures were highly
convergent (Fig. S2b) and showed a backbone RMSD
of 0.306, with 61 long-range NOE constraints defin-
ing the hairpin (Fig. S2c). Residues in the FLAG tag
did not interact with the biological unit (Fig. S2c).
The lowest energy calculated p7 structure (Fig. 1A)
is entered into the Protein Data Bank (ID: 3ZD0),
and NMR data deposited (BMRB code: 18863). The
first leg of the hairpin comprises a p7 a-helix (Ib)
along with the a-helical flag tag (Ia), separated from
the two C-terminal a-helices (III, IV) by a turn-helix-
(II)-turn motif (Fig. 1B). The N-terminal helix (amino
acids [aa] 1-25, p7 sequence) orients such that the
His17 and nucleophilic Ser21 residues are aligned,
consistent with pore-lining orientation.15,22-24,27 This
“lumenal” face of the helix also contains a run of N-
terminal small/hydrophobic residues and Phe25 at the
cytosolic end, which may act as a molecular gate based
on hyperactive Phe25Ala mutants.15 The interhelical
loop extends from aa 26-37, and includes a short heli-
cal stretch from Ala29 to Lys33. The p7 C-terminus
comprises a longer helix (aa 37-57) kinked at Pro49,
and another short, highly flexible helix following a di-
Pro motif (Pro58/59). The trans-membrane region was
predicted by “Octopus” (see Supporting Experimental
Procedures, Ref. 8) to comprise Asn9-Ala29 (N-termi-
nus) and Ala37-Leu57 (C-terminus). The overall struc-
ture more closely resembled predictions from ssNMR
with regard to helical length, orientation, and the
length of the interhelical loop compared with sNMR
models, suggesting that MeOH induces a fold analo-
gous to that observed in lipid-like detergents.25,26
Drug-Protein Interactions Validate the Mono-
meric FLAG-p7 Hairpin Fold. Our previous in silico
modeling predicted that the rimantadine binding site
primarily comprises residues from both helices of a
single folded p7 hairpin, centered on the Leu20 resi-
due.15 Thus, despite clear differences between in silico
models and our NMR structure, we hypothesized that
drug interactions with both helices in solution would
indicate that an analogous peripheral drug binding site
existed, as well as corroborating the evidence support-
ing the FLAG-p7 hairpin fold (Fig. S1e).
We used a variant of NMR conservative chemical
shift mapping to investigate drug interactions, calculat-
ing a shift metric (Dppm) from minimal isotope-
weighted chemical shift changes that map peaks from
an assigned (apo/unbound) state spectrum onto those
of the unassigned (holo/drug-bound) state.33 Chemical
shift changes could occur through direct ligand inter-
actions, or by way of structural/dynamic changes upon
binding. For FLAG-p7 interacting with rimantadine,
Dppm 0.14 were deemed significant, with shift
changes of up to 0.8 ppm observed for some resi-
dues (Fig. S3). To gauge specificity, interactions were
repeated for Leu20Phe FLAG-p7,15 which conferred
resistance to isotopically labeled protein in dye release
assays (Fig. 2A). Accordingly, rimantadine induced sig-
nificant Dppm in the region neighboring Leu20 for
wild-type, but not Leu20Phe FLAG-p7, consistent
with this polymorphism directly preventing adaman-
tane binding (Fig. 2B). Accordingly, Leu20 was among
a number of residues from both helices in the central
portion of the hairpin experiencing significant shifts
(Fig. 2B,C), with Trp48, Leu50, and Gly46 also show-
ing particularly clear perturbations. Thus, while precise
composition of the Leu20-defined rimantadine binding
site differed from that predicted by in silico models,15
it comprised many of the same key residues, was
located at a similar position, and would likely face the
channel periphery in the context of an oligomer.
Importantly, the site comprised several residues with a
high degree of conservation across genotypes, such as
Gly46, Trp48, and Leu50. Interestingly, several addi-
tional shifts were apparent in the loop region and near
the N/C termini of the protein, which were absent for
Leu20Phe (Fig. 2B,C). It was not possible to deter-
mine whether these represent additional interaction
sites, or result from changes in the overall structure of
the molecule following rimantadine binding. However,
shifts were dependent on initial rimantadine binding
in the vicinity of Leu20, supporting this as the pri-
mary adamantane interaction surface. Furthermore, the
composite nature of this binding site supports that
FLAG-p7 adopts a hairpin fold in MeOH.
Generation of Structure-Guided p7 Channel
Models as In Silico Screening Templates. The
monomeric structure was used to generate an energy-
minimized heptameric model of the assembled p7
channel complex as a template for in silico compound
design. Energetically stable complexes resulted from p7
protomers being tilted with respect to the membrane
normal, consistent with ssNMR26 (Fig. 3A). Models
retained the predicted lumenal orientation of His17
and Phe25 (Fig. 3A) which caused lumenal constric-
tions, and were more energetically stable compared to
previous de novo models15,27 (NMR: 254,472 kcal/
mol; de novo: 217,806 kcal/mol). Critically, the allo-
steric adamantane binding site was apparent on the
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channel periphery (Fig. 3B, black dotted circle) and
contained many rimantadine-interacting residues (Figs.
2C, 3B, darker red indicating stronger changes). Sites
included Leu20 at the base of the pocket (Fig. 3B,C),
which, combined with its observed shift change in the
presence of drug (Fig. 2B,C) provides clear rationale
underpinning Leu20Phe rimantadine resistance in
genotype 1b.15,34 Interestingly, loop-proximal residues
observed to shift in the presence of rimantadine (Fig.
2C) centered on another peripheral cavity (Fig. 3C,
long-dashed circle). These overlapped with nonsynony-
mous polymorphisms in other genotype 1b patients
unresponsive to amantadine35 (Fig. 3C). It is possible
that both peripheral cavities interact with adamantanes,
although the Leu20Phe phenotype supports a primary
role for the original site, which accommodates riman-
tadine molecules more favorably than the second site
(Glide, >2 log10 difference). Thus, convergence of the
structure-guided model with observed/predicted drug
interactions supports the relevance of the FLAG-p7
monomer structure.
Structure-Guided Models Select p7 Inhibitors
With Genuine Potency. The heptameric model was
employed as a template for in silico compound screen-
ing, targeting the principle allosteric site (eHiTS, Sym-
BioSys). 250K compounds were ranked based on
predicted binding affinity and drug-like qualities and
the top 30 were selected for testing against genotype
Fig. 1. Solution NMR
structure of FLAG-p7. The
structure of isotopically
labeled FLAG-p7 (GT1b) was
calculated using a combined
chemical shift/NOE method-
ology (see Materials and
Methods). (A) Ribbon dia-
gram of lowest energy struc-
ture for monomeric FLAG-p7.
Yellow, FLAG-tag and poly-
linker sequence; gray, biologi-
cal unit. Sidechains for key
residues are shown, including
His17, Ser21, and Phe25
predicted to form part of the
lumenal surface in the chan-
nel complex,15,22,23 the con-
served basic residues Lys33
and Arg35, Pro49 which
forms a kink in the C-
terminal helix. (B) Secondary
structure characteristics of
calculated solution NMR
structure. Black bars show
unambiguous restraints, gray
bars show restraints that are
detectable but with more
than one possible
assignment.
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Fig. 2. Validation of p7 NMR structure in methanol using specific drug interactions. (A) Isotopically labeled wild-type or Leu20Phe FLAG-p7
was tested for rimantadine sensitivity in dye release assays. Black lines, protein only; red line, protein plus 40 mM rimantadine; L, liposomes
only; S, solvent control. (B) 1H/15N HSQC spectra of wild-type and Leu20Phe p7 in the presence (red) or absence (black) of a 2 molar excess
of rimantadine. Specific minimal chemical shift changes in the presence/absence of drug were detectable in wild-type, but not Leu20Phe resist-
ant protein (see Supporting Fig. 2c for chemical shift change in parts per million (Dppm) values). (C) Positions of residues on monomeric struc-
ture seen to experience chemical shift changes in the presence of rimantadine, including Leu20. Graded color represents magnitude of Dppm;
pink (0.14-0.25), red (0.25-0.5), dark red (0.51).
Fig. .3.
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1b p7 in vitro. Twelve hits showed activity at concentra-
tions >100-fold lower (250 nM) than the rimantadine
prototype control (median inhibitory concentration
[IC50] 40 mM) (Fig. 4A). Hits were tested for effects
on Huh7 cell culture toxicity and off-target effects
against subgenomic luciferase replicons (Fig. S5). 400
nM was selected to provide a minimal 10-fold assay
window to test effects on particle secretion.
Selected compounds included adamantanes (LDS3
and 4), yet primarily comprised diverse chemotypes
(Fig. 4B,C; Table S2). Effects on HCV particle pro-
duction were tested against GT1b/2a HCV (J4/JFH-1)
72 hours post-electroporation (Fig. 4B). Aside from
LDS17, compounds achieved at least an IC50 at 400
nM, 100-fold lower concentration than rimantadine,
with many showing more pronounced effects (Fig.
4B). Notably, LDS19 and 21 were markedly more
potent, achieving a 90-95% reduction in infectious
titer.
Exemplars of predicted compound binding site
interactions compared with rimantadine are shown
(Fig. 4C). Each is distinct, yet overlapping, with the
majority of compounds forming H-bond interactions
with the backbone carbonyl of Gly46 (e.g., LDS3,
25), the hydroxyl group of Tyr45 (e.g., LDS19, 21,
Fig. 6B) or both (e.g., LDS20). LDS24 extends
beyond the primary allosteric site into the secondary
cavity, where the tetrahydroquinoline portion is pre-
dicted to bind to the channel through a pi stacking
interaction with Trp30, whereas LDS23 is predicted to
bind to the protein through a number of nonpolar
Van der Waals contacts. Thus, the p7 allosteric site
can be targeted by structurally diverse molecules with
variable binding modes, providing considerable scope
for future drug discovery.
Specificity of Potent p7 Targeted Compounds. With
hits targeting the primary allosteric site, the rimanta-
dine resistance polymorphism Leu20Phe was predicted
to influence binding and so confirm specificity.15
LDS19 and 21 were titrated against Huh7 cells trans-
fected with both wildtype and Leu20Phe J4/JFH-1
RNA, and a corresponding right-shift in dose-response
curves was evident for the resistant mutant (Fig. 5A).
However, submicromolar concentrations of both com-
pounds effectively suppressed Leu20Phe infectious
virion production (Fig. 5A), unlike rimantadine, which
is ineffective at subcytotoxic concentrations.15 Suppres-
sion was also apparent during low multiplicity infec-
tion, where spread of Leu20Phe HCV was reduced by
50-60% in the presence of 400 nM LDS19/21, yet
remained insensitive to rimantadine (Fig. 5B). LDS19
and 21 represented attractive starting points for drug
development, provided that a robust structure-activity
relationship (SAR) could be established. Preliminary
modification of LDS21 R-groups was undertaken to
assess improvements in potency with reference to pre-
dicted interactions with the p7 structure/channel
model (Fig. 5C). Ten derivatives cleared MTT and
replicon screens and displayed statistically significant
improved antiviral effects at 400 nM, with LDS21.8
and 21.9 causing a >2 log10 reduction in secreted
infectivity (Fig. 5C). Importantly, neither initial hit
compounds (data not shown and Fig. S4c) nor
LDS21 derivatives caused any obvious defects in
HCV protein localization (Fig. 5D; Fig. S4d), poly-
protein processing (Fig. S4b), or the accumulation of
intracellular infectivity (Fig. S4a), consistent with the
specific targeting of the release of infectivity, as medi-
ated by p7 channel activity, confirming studies with
prototype inhibitors.15
Activities of Genotype 1b-Targeted Compounds
Against p7 From Other Genotypes. LDS21,
LDS21.8, and LDS21.9 were tested against Huh7 cells
transfected with a panel of chimeric HCV RNAs to
determine their potential development against other
genotypes (Fig. 6A). In general, while IC50 values were
increased compared with genotype 1b, they remained
in the low micromolar range, generating favorable
therapeutic ratios in the majority of cases (Table 2).
Interestingly, the Leu20Phe polymorphism appeared to
confer limited resistance to some novel compounds in
the case of genotype 1b, but this was not the case in a
genotype 2a JFH-1 context, where it enhanced suscep-
tibility. In addition, genotype 1a appeared more resist-
ant to novel compounds compared with all others
tested, despite reasonably high (82%) amino acid
Fig. 3. Construction of heptameric channel models based on monomeric p7 NMR structure. Energy minimized channel models were constructed
in Maestro (see Materials and Methods) by symmetrical arrangement of individual biological unit protomers with multiple rounds of energy minimiza-
tion. Stable structures resulted from a tilted orientation of individual protomers relative to the predicted membrane normal. The N-terminal helices
formed the channel lumen and the C-terminal helices stabilized the channel complex, consistent with previous models and predictions. (A) Left:
top-down surface view showing individual protomers as ribbons. His17 and Phe25 are highlighted projecting into the lumen. Right: side view cut-
away showing orientation of individual protomers, His17 and Phe25 highlighted and lumenal diameter indicated by the “Hollow” program.31 (B) Res-
idue positions in context of heptameric channel model seen to interact in NMR experiments (color grading as in Fig. 2C). (C) Amino acid changes
in patients nonresponsive to amantadine in two separate studies as indicated. Predicted rimantadine docking is shown for one of the seven primary
peripheral binding pockets (black dashed line) along with a potential secondary binding site (longer dashed circle).
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conservation with the J4 protein. Interestingly, while
IC50 and IC90 values were close together for genotype
1b, the latter were often much higher in other geno-
types, suggesting that effective saturation of the system
was harder to achieve in these contexts.
To investigate the possible mechanisms underpinning
inhibitor effects, we constructed additional channel
models for each genotype based on the J4 structure
model and assessed the predicted binding of both riman-
tadine and LDS21 (Fig. 6B). While it was not possible
to determine an obvious cause of varied inhibitor effects,
it was clear that even minor variations within the periph-
eral binding site altered the way in which both com-
pounds interacted with the protein. Complete
understanding of the basis of genotype-dependent inhib-
itor sensitivity will likely require more extensive analysis
using a wide array of compounds to establish a structure-
activity relationship in each instance.
Discussion
Here we solved a monomeric HCV p7 solution
structure, yielding a relevant drug-binding hairpin con-
formation. In so doing, we validated the presence of
an allosteric drug binding cavity reminiscent of that
predicted by in silico modeling15 and demonstrated
that this could be exploited for rational development
of novel p7 inhibitors. In turn, resultant compound
potency not only supports the accuracy and relevance
of the structure, but also highlights p7 as a viable tar-
get for the development of direct-acting antivirals
(DAA).
Our solution structure benefited from the favorable
environment provided by MeOH as a solvent which,
unlike conditions in previous studies,24 allowed a hair-
pin to form. FLAG-p7 was monodisperse in MeOH,
but not in the membrane-mimetic detergent DHPC.
This differs from ssNMR studies where DHPC pre-
served p7 monomers,25,26 possibly relating to different
purification methods19,36 or even the presence of the
FLAG tag. Nevertheless, despite well-dispersed and
fully assignable spectra, traditional structure calculation
methods could not unambiguously resolve the final p7
hairpin, requiring a novel combination of chemical
shift and NOE protocols to reach a satisfactory struc-
tural solution. This approach may be of value to fur-
ther studies of membrane proteins, particularly those
containing more than one trans-membrane helix. This
method is supported by the recent ssNMR structure of
the GPCR CXCR1, which was derived using a similar
protocol.37
The monomer structure showed good agreement
with structural/functional studies, including predicted
lumen formation by the p7 N-terminal helix,15,23,24,27
with alignment of His17, Ser21, and Phe25. Further-
more, the content and orientation of p7 helical
domains were reminiscent of those proposed by mem-
brane ssNMR,26 suggesting that MeOH induced a
protein fold closely resembling that formed in the
bilayer. Furthermore, drug interactions in solution and
a heptameric structure-model supported a peripheral
adamantane binding site analogous to that predicted
by de novo modeling. Drug binding at this site would
likely stabilize closed p7 channels by way of an alloste-
ric mechanism, similar to that proposed in controver-
sial studies of IAV M2.38,39 However, as rimantadine
and other prototype inhibitors are only effective
against p7 in the mid-micromolar range,13,15,16 com-
pounds with improved potency tailored to the alloste-
ric site would further support its relevance for antiviral
development.
Two additional p7 NMR structures were published
during the revision of this article. The first described
the structure of a complete genotype 5a hexameric p7
channel complex in DHPC micelles,40 with similarity
to EM reconstructions of hexameric genotype 2a chan-
nels in the same environment.20 The unusual structure
of this complex could not have been predicted by stand-
ard modeling as monomeric hairpins are not present,
protomers instead forming an extended “staple-like”
structure that interacts with adjacent n11, 2, and 3
protomers. Accordingly, interhelix distance restraints for
individual protomers differ markedly from both our
own NOE-defined values, as well as those derived from
Fig. 4. Selection of novel, structurally diverse p7 inhibitors. In silico screening using p7 channel models as a template derived a range of
Lipinski-compliant potential inhibitors of the p7 channel complex and the top 30 were selected for testing as proof-of-principle. (A) Liposome
dye release assay showing endpoint values compounds with activity against wild-type p7 at 250 nM that were subsequently selected for cell cul-
ture studies. Results are the average of two separate experiments with each condition in duplicate and are expressed as a percentage of the
untreated protein value following baseline subtraction (liposomes alone). S, solvent control. p7 treated with one rimantadine IC50 (40 lM) is
included as comparison, novel compounds tested at 250 nM. (B) Inhibition of infectious virus release from Huh7 cells transfected with J4/JFH-1
RNA using novel compounds (400 nM). Selected compounds show minimal effect on intracellular infectivity, replicon replication and have no
toxic effects (see Supporting Fig. 5 and Table 2). Chart shows the average released titers from duplicate wells originating from at least two sepa-
rate experiments, error bars represent standard error between experiments. Rimantadine and the alkylated imino-sugar NN-DNJ at IC50 are
shown for comparison (40 and 20 lM, respectively). (C) Structures of selected initial hit compounds. (D) Predicted docking poses of rimanta-
dine novel compounds at the allosteric binding site (calculated in Glide, Schrodinger). Key interacting residues are highlighted.
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published ssNMR studies. Furthermore, residues at
position 17 and 25 are not oriented toward the lumen,
which is significantly wider than models herein, and the
polybasic C-terminus of the protein is embedded within
the hydrophobic environment. However, in agreement
with our studies, a peripheral adamantane site was sup-
ported by both NMR and biophysical techniques,
although channel formation and drug sensitivity of the
5a channel was not demonstrated.
Given that the monomeric fold of p7 has been
extensively characterized as a hairpin, it remains
unclear as to how protein rearrangements might occur
between the monomer and hexamer forms of the pro-
tein. Another possibility is that hexameric and hepta-
meric p7 complexes may involve different p7
monomeric conformations, which could be especially
relevant when considering genotype-dependent inhibi-
tor sensitivity individual HCV genotypes appear to
favor predominantly one or the other form.19,20
Unfortunately, we did not include genotype 5a in our
genotype analysis, yet its 53% similarity to genotype
1b channels is comparable to that of the 4a protein. It
will be of significant interest to establish whether the
genotype 5a hexamer structure can similarly be used as
a template for structure-guided inhibitor design.
The second reported p7 sNMR structure from the
Opella laboratory describes monomeric genotype 1b
protein (J4 isolate) within DHPC micelles at pH 4.0
(Cook et al., Biochemistry, 2013, Epub ahead of
print). Monomeric stoichiometry was inferred by
NMR data analysis, yet why this differs from both our
own studies and the Chou study is unclear. Interest-
ingly, this structure also required a combined chemical
shift/NOE based protocol as described here. While
pdb and NMR data are currently unavailable, the heli-
cal composition of the DHPC monomer appears to
differ from both our own neutral pH structure, as well
as the groups previous ssNMR studies.26 It is tempting
to speculate that this solution may represent the fold
of the J4 protein in the acidified state. Comparison
with our structure may therefore provide insight into
the gating mechanisms of genotype 1b p7 channel
complexes. This study also investigated inhibitor bind-
ing, although the peripheral adamantane site was
occluded by detergent micelles.
The successful selection of GT1b p7 inhibitors with
potent effects in vitro and in culture compared to pro-
totypes was surprising, yet this supported the relevance
of both the monomeric structure and the derived hep-
tameric channel model. Moreover, improved com-
pound potency corresponded to a much higher degree
of predicted fit within the allosteric site compared
with rimantadine. Consistent with modeling stud-
ies,15,34 Leu20 resided within the allosteric site on the
structure-guided heptamer, allowing the Leu20Phe
polymorphism to illustrate site specificity for novel
compounds. LDS19 and 21 effectively suppressed
Leu20Phe particle release at submicromolar doses,
indicative of their improved binding capacities. LDS21
derivatives also displayed activity against other HCV
genotypes, yet were less effective against GT1a p7,
which we recently showed to display more pore-like
behavior compared with 1b channels, which are more
M2-like.28,41 This pore-like shift in equilibrium
towards the open state may reduce the number of
closed channel complexes to which allosteric inhibitors
can bind, although our genotype modeling indicated
that varied binding pocket conformations may also
influence compound efficacy. This may be further
complicated by the formation of either hexameric or
heptameric complexes. Nevertheless, LDS21 derivatives
demonstrate the potential for variable potency within
the series and confirms that molecules tailored to the
allosteric site show great potential for drug discovery.
Interestingly, the effects of LDS compounds in vitro
did not necessarily correlate with their effects in cul-
ture (Fig. 4). As compounds are administered as a sin-
gle dose at the beginning of a 72-hour experiment, we
Fig. 5. Specificity of novel p7 inhibitors. Screening lead hits LDS19 and 21 were examined for specificity against wild-type and rimantadine
resistant HCV. (A) Titration of LDS 19 and 21 against Huh7 cells transfected with both wild-type (diamonds) and Leu20Phe (squares) J4/JFH-1
RNA, showing effects on released infectivity. Graph plots the average released titers from duplicate wells from at least two separate experiments,
normalized to the 100% untreated value. Error bars represent normalized percent error of the mean between experiments (*P< 0.05). (B) Effects
of p7 inhibitors on HCV spread following infection at low M.O.I (0.0001 FFU/cell). Huh7 cells were infected in triplicate overnight with wild-type
(black) and Leu20Phe (white) J4/JFH-1 and then media replaced after extensive washing with that containing inhibitors. Fluorescent NS5A foci
were counted at 72 hours postinfection. Histogram shows the average counts for two experiments with triplicate wells normalized to 100%
untreated value to allow comparison between viruses. Error bars represent normalized percent error of the mean (*P< 0.05, **P< 0.01). (C)
The northern and southern R-groups of LDS21 were rationally altered to determine tolerances for molecular structures and fit within the
structure-guided channel model peripheral binding site. Activities of a limited series of LDS21 structural analogs against both wild-type (black)
and Leu20Phe (white) J4/JFH-1, normalized to untreated values. Results are the average of two separate experiments with duplicate wells and
error bars are normalized percent error of the mean between experiments. (D) Immunofluorescence staining for core (green Alexa-fluor 488 nm)
and NS5A (red, Alexa-fluor 565 nm) in huh7 cells 72 hours posttransfection of J4/JFH-1 RNA following treatment with 4 mM LDS21, 21.8, and
21.9.
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predict that differences in cellular uptake and/or turn-
over may influence the effectiveness of the compounds.
Determining metabolic stability will form a critical ele-
ment of expanding the series.
Skepticism concerning p7 inhibitors arose follow-
ing clinical trials employing the weak prototype
inhibitor, amantadine,13,14 alongside interferon and
ribavirin, with little measurable response.17,18 This
was perhaps unsurprising as interferon-insensitive
HCV could continue to replicate and produce escape
variants.42 Nevertheless, given that even weak selec-
tive pressure against p7 can drive HCV to escape,
evidenced by the selection of both Leu20Phe34 and
potentially other polymorphisms,35 the prospect of
employing targeted, potent molecules becomes highly
attractive.
Fig. 6. Effects of novel inhibitors against multiple HCV genotypes. (A) LDS21, 21.8, and 21.9 were titrated against Huh7 cells transfected
with chimeric HCV RNAs and secreted titers determined by focus forming assay. Results are representative of two independent experiments and
are the average of triplicate wells. Error bars represent standard deviations. (B) Channel models for each individual HCV genotype analyzed in
(A) were generated in order to predict the influence of polymorphisms upon the binding of rimantadine and LDS21. Changes in sequence
strongly influenced the docking poses adopted by molecules, but no clear correlation with inhibitor potency was evident.
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Targeted p7 inhibitors could comprise effective com-
ponents of interferon-free DAA regimens and suppression
of Leu20Phe resistance by LDS19 and 21 suggests that
the genetic barrier to HCV escape may be much higher.
Interestingly, an amiloride-based genotype 1a p7 inhibi-
tor selected from a bacterial screen, BIT225,43 is cur-
rently in clinical trials combined with interferon and
ribavirin. Early results appear encouraging, albeit in a
small number of patients. However, the mode of action
for BIT225 is unknown and no published data exist dem-
onstrating its efficacy against HCV in culture. Neverthe-
less, compounds described herein represent a step-change
in potency appropriate for drug discovery. Given recent
phase 3 setbacks for some HCV DAAs, it is clear that
continued identification and development of drug targets
will be critical for the long-term management of HCV
disease. Thus, our p7 structure not only represents a valu-
able tool for investigating channel function, but confirms
that p7-targeted drug discovery should provide a further
valuable component to future HCV antiviral therapy.
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